Use of fibrin glue in the treatment of pneumothorax in premature infant

Fibrin Sealant: The Only Approved Hemostat, Sealant, and Adhesive—a Laboratory and Clinical Perspective

“…This group found that: the vast majority of patients (91%) had no air leaks allowing their chest tube removal on the first postoperative day; removal of chest tubes one day after cessation of any observed air leak (one day of prophylactic drainage) resulted in a low level of chest tube reinsertion for recurrent air leak (2.9%); and the need for recurrent chest tube insertion was greater in patients undergoing segmentectomy than lobectomy ( P = 0.04). A case report of treating bilateral pneumothorax in a premature infant documented the use of a low calcium (0.59%) concentration fibrin sealant via the chest tubes to eliminate the air leaks and avoid reported complications such as hypercalcemia and bradycardia [169]. A rare case of pneumothorax associated with chronic graft versus host disease (cGVHD) was successfully treated with fibrin sealant pleurodesis under fluoroscopic guidance when prior treatments with autologous blood via chest tubes had failed [170].…”

Fibrin glue pleurodesis for pneumothorax in extremely preterm infants: a case report and literature review

“…Pneumothorax (PTX) is one of the major complications in extremely preterm infants with respiratory failure and is associated to high mortality and morbidity [ 1 , 2 ]. After the introduction of surfactant replacement therapy, its incidence is dropped and now is around 1–2% [ 1 , 2 ].…”

“…Pneumothorax (PTX) is one of the major complications in extremely preterm infants with respiratory failure and is associated to high mortality and morbidity [ 1 , 2 ]. After the introduction of surfactant replacement therapy, its incidence is dropped and now is around 1–2% [ 1 , 2 ]. Asymptomatic PTX without underlying pulmonary disease does not require any treatment, but in case of symptomatic PTX insertion of a chest tube and air drainage are required [ 1 ].…”

“…After the introduction of surfactant replacement therapy, its incidence is dropped and now is around 1–2% [ 1 , 2 ]. Asymptomatic PTX without underlying pulmonary disease does not require any treatment, but in case of symptomatic PTX insertion of a chest tube and air drainage are required [ 1 ]. Although necessary, chest tube placement can lead to several complications in neonates, such as lung injuries, insertion site and pulmonary infections, phrenic nerve paralysis, chylothorax, and hemorrhagic pericardial effusion [ 1 ].…”

“…Asymptomatic PTX without underlying pulmonary disease does not require any treatment, but in case of symptomatic PTX insertion of a chest tube and air drainage are required [ 1 ]. Although necessary, chest tube placement can lead to several complications in neonates, such as lung injuries, insertion site and pulmonary infections, phrenic nerve paralysis, chylothorax, and hemorrhagic pericardial effusion [ 1 ]. Usually chest tube drainage, positioning with the affected side down, low lung volume strategy, and high frequency oscillatory ventilation are effective treatment of PTX and allow its recovery in few days but, sometimes, mainly in patients with large bronchopleural fistulas, it can persist for several days [ 2 ].…”